Targeting mitochondria with small molecules: A promising strategy for combating Parkinson's disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Pal C;Pal C
  • Source:
    Mitochondrion [Mitochondrion] 2024 Nov; Vol. 79, pp. 101971. Date of Electronic Publication: 2024 Sep 30.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100968751 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8278 (Electronic) Linking ISSN: 15677249 NLM ISO Abbreviation: Mitochondrion Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam ; New York : Elsevier Science, c2001-
    • Subject Terms:
    • Abstract:
      Parkinson's disease (PD), a neurodegenerative disorder, is one of the most significant challenges confronting modern societies, affecting millions of patients globally each year. The pathophysiology of PD is significantly influenced by mitochondrial dysfunction, as evident by the contribution of altered mitochondrial dynamics, bioenergetics, and increased oxidative stress to neuronal death. This review examines the potential use of small molecules that target mitochondria as a therapeutic approach for treating PD. Progress in mitochondrial biology has revealed various mitochondrial targets that can be modulated to restore function and mitigate neurodegeneration. Small molecules that promote mitochondrial biogenesis, enhance mitochondrial dynamics, decrease oxidative stress, and prevent the opening of the mitochondrial permeability transition pore (mPTP) have shown promise in preclinical models. Additionally, targeting mitochondrial quality control mechanisms, such as mitophagy, provides another therapeutic approach. This review explores recent research on small molecules targeting mitochondria, examines their mechanisms of action, and assesses their potential efficacy and safety profiles. By highlighting the most promising candidates and addressing the challenges and future directions in this field, this review aims to offer a comprehensive overview of current and future prospects for mitochondrial-targeted therapies in PD. Ultimately, treating mitochondrial dysfunction holds significant promise for developing disease-modifying PD medications, giving patients hope for better outcomes and improved quality of life.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 Elsevier B.V. and Mitochondria Research Society. All rights reserved.)
    • Contributed Indexing:
      Keywords: Mitochondrial dysfunction; Oxidative stress; Parkinson’s disease; Reactive oxygen species; Small molecule
    • Accession Number:
      0 (Small Molecule Libraries)
    • Publication Date:
      Date Created: 20241002 Date Completed: 20241116 Latest Revision: 20241125
    • Publication Date:
      20241126
    • Accession Number:
      10.1016/j.mito.2024.101971
    • Accession Number:
      39357561